CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 142 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,385 | +957.3% | 92,886 | +516.0% | 0.06% | +983.3% |
| Q1 2023 | $131 | -61.0% | 15,080 | -71.8% | 0.01% | -68.4% |
| Q4 2022 | $336 | -99.8% | 53,550 | -8.8% | 0.02% | +58.3% |
| Q3 2022 | $206,000 | -28.5% | 58,740 | -39.8% | 0.01% | -45.5% |
| Q2 2022 | $288,000 | +93.3% | 97,594 | +103.3% | 0.02% | +120.0% |
| Q1 2022 | $149,000 | -6.3% | 47,994 | +1.8% | 0.01% | -50.0% |
| Q4 2021 | $159,000 | +101.3% | 47,134 | +117.4% | 0.02% | +81.8% |
| Q3 2021 | $79,000 | -44.8% | 21,684 | -31.1% | 0.01% | -76.1% |
| Q1 2021 | $143,000 | +107.2% | 31,470 | +160.3% | 0.05% | +130.0% |
| Q4 2020 | $69,000 | -71.8% | 12,090 | -64.3% | 0.02% | -74.4% |
| Q3 2020 | $245,000 | -11.6% | 33,830 | -57.4% | 0.08% | -17.0% |
| Q2 2020 | $277,000 | – | 79,350 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |